NAMS
NewAmsterdam Pharma Company N.V.
22.80$
-1.7%
vs. previous close
Closing price · As of: Oct 5, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | -72.7% | +74.5% | +62.7% | +1,177.4% | -56.1% | -76.7% | +542.9% | -98.2% | -90.8% | +9,400.0% | +21.7% | – | |
| – | – | – | +18.3% | – | – | – | – | +42.2% | -7.8% | +747.5% | – | – | |
| – | -72.7% | +72.6% | +64.4% | +1,177.4% | -56.1% | -76.7% | +542.9% | -98.2% | -107.8% | – | +45.7% | – | |
| – | -4.8% | +2.8% | -9.5% | -7.0% | -2.3% | +28.2% | -38.5% | +12.6% | +24.6% | -2.8% | +11.1% | – | |
| – | -13.9% | +37.9% | +24.2% | +16.6% | +158.2% | -23.4% | +0.4% | -10.1% | +11.6% | -14.3% | +14.7% | – | |
| – | -1.2% | +8.6% | -2.6% | -1.3% | +3.5% | +28.4% | -23.8% | +1.3% | +18.9% | -7.6% | +12.5% | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +79.8% | -61.5% | +27.9% | +33.0% | +182.4% | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | +111.4% | -11,574.1% | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – | |
| – | – | – | – | – | – | – | – | – | – | – | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 5, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.